The Microbiome Heals and Harms Chronic Wounds. Here’s How to Tip the Balance.
The bacteria living in a chronic wound are not passive bystanders: some actively stall healing while others quietly drive tissue repair. A new review maps both sides of that equation and points toward microbiome-based treatments that could change wound care.
Chronic wounds have long been framed as a circulation problem, a metabolic problem, or an infection problem. A sweeping new review published in Cell Communication and Signaling reframes the conversation: the microbial communities colonizing these wounds are not simply a downstream complication but a central driver of whether a wound closes or lingers for months. The same microbiome that can sustain chronic inflammation and resist antibiotics can, under different conditions, actively promote tissue regeneration.
How Wound Bacteria Either Repair or Destroy Tissue
The dual role of wound microbial communities has been documented in other contexts, but this review by Deng, Qian, Liu, and colleagues draws the sharpest picture yet of the opposing forces at work. Beneficial residents such as Staphylococcus epidermidis and Lactobacillus plantarum stimulate the production of antimicrobial peptides and calibrate cytokine signaling in ways that favor tissue repair. They occupy colonization niches, essentially crowding out pathogens before an infection can establish.
On the other side of that ledger sit opportunistic pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis. These organisms delay wound closure through proteolytic activity that degrades the extracellular matrix, chronic inflammatory signaling that keeps the wound in a perpetual repair-initiation loop, and, most critically, biofilm formation. Biofilms are now implicated in up to 60% of chronic wounds, where they confer resistance to both antibiotics and host immune defenses, making conventional treatment strategies increasingly ineffective.
The Public Health Cost of Wounds That Won't Close
Understanding the microbial stakes matters because chronic wounds are far more prevalent than most people realize. Chronic wounds affect 1 to 2% of the population in developed countries, and the U.S. healthcare system alone spends approximately $25 billion annually managing them. Patients with diabetes, venous insufficiency, or pressure injuries face the highest risk, and many experience wounds that persist for years, eroding quality of life and increasing mortality risk.
Standard care, including debridement, moisture management, and systemic antibiotics, addresses the wound environment but not its microbiology in any targeted way. The review argues that ignoring the microbiome means leaving one of the most influential variables in wound healing largely unmanaged.
Reshaping the Wound Microenvironment With Probiotics
The most forward-looking section of the review covers probiotic interventions: the deliberate introduction of beneficial microorganisms to shift the wound microbiome toward a pro-regenerative state. Emerging evidence cited by Deng and colleagues indicates that probiotics can suppress pathogenic colonization, reshape local metabolic activity, and recalibrate immune responses in the wound bed. The mechanisms are specific rather than generic: certain strains modulate cytokine production directly, others produce short-chain fatty acids that alter the pH and oxygen availability that pathogens depend on, and others compete at the adhesion level, preventing pathogenic biofilms from forming in the first place.
Topically applied probiotic formulations are the primary delivery route under investigation, allowing high local concentrations without the systemic exposure of oral routes. Some experimental approaches combine probiotics with bacteriophages, viruses that selectively target and lyse bacterial pathogens, to address established biofilms that probiotics alone cannot penetrate.
Open Questions About Clinical Validation and Long-Term Efficacy
The optimism in this space is real but premature. As clinical validation for microbiome-modulating wound therapies remains limited, the field is still largely working from in vitro studies, animal models, and small human trials. Key questions remain unanswered: which probiotic strains are most effective for specific wound types, how to maintain viable microbial populations in the hostile chemical environment of a chronic wound, and whether reshaping the wound microbiome in the short term translates into durable improvement in closure rates.
Standardization is another problem. Wound microbiome studies vary enormously in sampling technique, sequencing depth, and how they define outcomes, making it difficult to compare results across research groups or build the kind of evidence base that would justify widespread clinical adoption.
What Comes Next in Microbiome-Targeted Wound Care
The review by Deng and colleagues positions the wound microbiome as both a biomarker and a therapeutic target, a framing with concrete implications for how wounds are assessed and treated. On the diagnostic side, routine microbiome profiling of chronic wounds at the point of care could identify which patients carry high-biofilm pathogen loads early enough to intervene before resistance patterns entrench. On the treatment side, precision probiotic protocols, potentially combined with bacteriophage therapy, represent the most promising near-term avenue.
Larger randomized controlled trials are the obvious next step, and the review calls for them explicitly. Given the $25 billion annual cost burden and the millions of patients cycling through wound care clinics without durable resolution, the pressure to move from bench to bedside is substantial. The science is not there yet, but the map of the terrain, where the allies are, where the enemies hide, and which levers can be pulled, is considerably clearer than it was even a few years ago.
